GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » BioPlus Acquisition Corp (NAS:BIOS) » Definitions » Net Issuance of Preferred Stock

BioPlus Acquisition (BioPlus Acquisition) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Jun. 2023)


View and export this data going back to 2022. Start your Free Trial

What is BioPlus Acquisition Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

BioPlus Acquisition's net issuance of preferred for the three months ended in Jun. 2023 was $0.00 Mil. The number is 0, which means that BioPlus Acquisition has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

BioPlus Acquisition's net issuance of preferred for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.

BioPlus Acquisition Net Issuance of Preferred Stock Historical Data

The historical data trend for BioPlus Acquisition's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioPlus Acquisition Net Issuance of Preferred Stock Chart

BioPlus Acquisition Annual Data
Trend Dec21 Dec22
Net Issuance of Preferred Stock
- -

BioPlus Acquisition Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioPlus Acquisition Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioPlus Acquisition Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of BioPlus Acquisition's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

BioPlus Acquisition (BioPlus Acquisition) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » BioPlus Acquisition Corp (NAS:BIOS) » Definitions » Net Issuance of Preferred Stock
Comparable Companies
SBII GWII AHPA TACA CAS MCAA CORS AKIC CFFE TOAC GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ
Traded in Other Exchanges
N/A
Address
260 Madison Avenue, Suite 800, New York, NY, USA, 10026
Website
BioPlus Acquisition Corp is a blank check company.
Executives
Steven C. Fletcher 10 percent owner C/O LEE ENTERPRISES, INCORPORATED, 4600 EAST 53RD STREET, DAVENPORT IA 52807
Explorer Parent Llc 10 percent owner 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012
Founder Holdings Llc 10 percent owner 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012
Alex Serge Vieux 10 percent owner C/O COMPUTER ASSOCIATES INTER INC, ONE COMPUTER ASSOC PLAZA, ISLANDIA NY 11749
Bioplus Sponsor Llc 10 percent owner 544 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94010
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080
Louis G Lange director 3172 PORTER DRIVE, PALO ALTO CA 94034
Ross Haghighat director, officer: CEO and CFO C/O ADURO BIOTECH, INC., 626 BANCROFT WAY, 3C, BERKELEY CA 94710
Ronald W Eastman director 335 BRYANT STREET, THIRD FLOOR, PALO ALTO CA 94301
Shawn Cross director 1825 K STREET SUITE 510, WASHINGTON DC 20006
Jonathan Rigby director, officer: Chief Business Officer ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
Glen Giovannetti director UNIT 6706, THE CENTER, 99 QUEEN'S ROAD CENTRAL, HONG KONG K3 00000